We are now in the process of final database close activities and remain on track to report topline results from this study in December or possibly in early January 2021 to coincide with seasonal healthcare industry conferences. Initiated a Phase 2 Open Angle Glaucoma Trial; Recruiting Ahead of Schedule Announced Partnership with I-SPY to Participate in a Clinical Trial to Tre ... CINCINNATI , Aug. 10, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on deve ... CINCINNATI , Aug. 04, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO) and The U.S. Government operating through th ... CINCINNATI , June 24, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on deve ... CINCINNATI , June 08, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ARPO), today announced that, due to the publi ... CINCINNATI , June 08, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on deve ... SAN FRANCISCO and CINCINNATI , May 27, 2020 /PRNewswire/ -- Aerpio Pharmaceuticals, Inc. ("Aerpio") (Nasdaq: ARPO) and Quantum Leap Healthcare C ... Aerpio Received an Immediate Payment of $15 million CINCINNATI , May 12, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ... Razuprotafib (formerly known as AKB-9778) Phase 2 Open Angle Glaucoma Trial on Track for Third Quarter Start CINCINNATI , May 07, 2020 (GLOBE NEWSWIR ... Plan to advance AKB-9778 topical formulation into a Phase 2 trial in open angle glaucoma with top line results expected during the first quarter of 20 ... CINCINNATI , March 12, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compoun ... Data presented at the 9 th Annual Glaucoma 360 New Horizons Forum CINCINNATI --(BUSINESS WIRE)--Feb. 7, 2020-- Aerpio Pharmaceuticals, Inc. (Nasdaq: A ... CINCINNATI --(BUSINESS WIRE)--Jan. 8, 2020-- Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds ... CINCINNATI --(BUSINESS WIRE)--Nov. 7, 2019-- Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds ... CINCINNATI --(BUSINESS WIRE)--Oct. 21, 2019-- Aerpio Pharmaceuticals, Inc. (NasdaqCM: ARPO), a biopharmaceutical company focused on developing compoun ... CINCINNATI --(BUSINESS WIRE)--Oct. 10, 2019-- Aerpio Pharmaceuticals, Inc. (Nasdaq:ARPO), a biopharmaceutical company focused on developing compoun ... CINCINNATI --(BUSINESS WIRE)--Aug. 8, 2019-- Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds ... CINCINNATI --(BUSINESS WIRE)--Jun. These findings suggest that SARS-CoV-2 infection facilitates the induction of endotheliitis in several organs as a direct consequence of viral involvement (as noted with presence of viral bodies) and of the host inflammatory response. NEJM 2017. Professor of Surgery, Immunology and Bioengineering, Vice Chair of Research, Department of Surgery, University of Pittsburgh, Professor of Surgery, St. Michael's Hospital, University of Toronto, Professor of Medicine, Director, Center for Vascular Biology Research, Associate Vice Chair for Research, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School. The Company is also evaluating development options for ARP-1536, a humanized monoclonal antibody, for its therapeutic potential in the treatment of diabetic vascular complications including nephropathy and diabetic macular edema (“DME”). To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the start time. GB004 is being developed by AKB-4924’s exclusive licensor, Gossamer Bio, Inc. (Nasdaq: GOSS). This therapeutic could result in fewer COVID-19 patients requiring mechanical ventilation, earlier recovery with decreased time in the hospital and ICU and an overall reduction in morbidity and mortality”. all of which could improve the physiology and outcomes of patients with COVID-19. Finally, the Company has exclusively out-licensed AKB-4924 (now called GB004), a first-in-class, orally bioavailable, gut targeted small molecule hypoxia inducible factor (HIF) prolyl hydroxylase inhibitor. The study with LY3127804 is expected to begin later this month at multiple sites in the United States (NCT04342897). GB004 is an oral, gut-targeted HIF-1 alpha stabilizer that has been shown to improve disease indices in multiple models of inflammatory bowel disease. Professor of Medicine, Melinda Owen Bass Chair in Medicine, Associate Vice Chancellor for Research, Vanderbilt University Medical Center, Professor of Medicine, Professor of Pharmacology and Cancer Biology, Duke University. In clinical trials, SC razuprotafib has shown clear evidence of target engagement and vascular stabilization with excellent safety profile in healthy volunteers and diabetic patients (n = 352) dosed SC twice daily for up to 48 weeks. Figure 1: ARDS pathophysiology and Tie2. COVID-19 Program: Aerpio Awarded MTEC Grant. Investors should consult all the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents the Company files with the SEC available at www.sec.gov. Months into the COVID-19 pandemic, just three therapeutics have been approved to treat COVID-19: dexamethasone in the United Kingdom and Japan; Avigan (favilavir) in China, Italy and Russia; and Veklury (remdesivir) in the United States, Japan and Australia. Aerpio Pharmaceuticals is a biopharmaceutical company focused on leveraging Tie2 activation for ocular disease and vascular stabilization. Such forward-looking statements include, among other things, the Company’s product candidates, including razuprotafib, ARP-1536 and the bispecific antibody asset, the clinical development plan therefor and the therapeutic potential thereof, the Company’s plans and expectations with respect to razuprotafib and the development therefor and therapeutic potential thereof in addressing COVID-19 and the intended benefits from the Company’s collaboration with Gossamer Bio for GB004, including the continued development of GB004 and the milestone and royalty payments related to the collaboration. There, he championed the development of novel therapies for patients with melanoma and kidney cancer and the in vivo application of IL-2, IL-4, and IL-7 as cancer therapies. Dr. Lotze developed adoptive transfer of Natural Killer Cells (NKs)/lymphokine-activated killer cells and tumor-infiltrating lymphocyte therapies and launched gene therapy efforts that continued when he moved to the University of Pittsburgh. The Company is also evaluating development options for ARP-1536, a humanized monoclonal antibody, for its therapeutic potential in the treatment of diabetic vascular complications including nephropathy and diabetic macular edema (“DME”). Razuprotafib is a novel small molecule Tie2 activator that enhances endothelial function and stabilizes blood vessels, including pulmonary and renal vasculature. Dr. Self is an Associate Professor at Vanderbilt University Medical Center, a practicing emergency physician, and clinical trialist who specializes in critical care clinical trials. He will serve as the lead investigator for the Clinical Coordinating Center for the Phase 2 trials of AKB-9778. Made In NYC |
About Razuprotafib (formerly known as AKB-9778). I-SPY COVID-19 (I-SPY2)Leadership: Michael Matthay, MD, Professor of Medicine UCSF; Carolyn Calfee, MD, Professor of Medicine and Critical Care UCSF; Nuala Meyer, MD Associate Professor of Medicine, University of Pennsylvania; and Laura Esserman, MD, Co-Principal Investigator of I-SPY2, Member, QLHC Board of Directors, Aerpio (razuprotafib = AKB-9778) was one of four drugs selected to be included in the I-SPY platform trial and is the highest priority drug on their platform (dozens of programs were evaluated), COVID Grants: Background on MTEC and I-SPY (QLHC) Organizations, Medical Technology Enterprise Organization - MTEC, I-SPY - Quantum Leap Healthcare Collaborative (QLHC), Have selected 4 drugs to include in COVID Network Trial with Aerpio's drug as top priority, "Aerpio's drug is the one that most excites the investigators." All rights reserved. Such factors include, among others, the continued development of GB004 and maintaining and deriving the intended benefits of the Company’s collaboration with Gossamer Bio; ability to continue to develop razuprotafib or other product candidates, including in indications related to COVID-19; the inherent uncertainties associated with the drug development process, including uncertainties in regulatory interactions, the design of planned or future clinical trials, commencing clinical trials and enrollment of patients in clinical trials; obtaining any necessary regulatory clearances in order to commence and conduct planned or future clinical trials; the impact of the ongoing COVID-19 pandemic on the Company’s business operations, including research and development efforts and the ability of the Company to commence, conduct and complete its planned clinical activities; and competition in the industry in which the Company operates and overall market conditions; and the additional factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2019, as updated by our subsequent Quarterly Reports on Form 10-Q and our other subsequent filings with the SEC.
Louis Nye Net Worth,
Best Beef Lasagna Recipe,
Adjectives For Bees,
Wholesale Coffee Roasters,
Gordon Ramsay Restaurants Prices,
Canopy Bed Frame,
Prince Of Persia Warrior Within Remastered Ps4,
Global Radio Auction,
The End Fortnite Music Piano,